330 related articles for article (PubMed ID: 30245690)
1. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
Takami M; Ihara F; Motohashi S
Front Immunol; 2018; 9():2021. PubMed ID: 30245690
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.
Nagato K; Motohashi S; Ishibashi F; Okita K; Yamasaki K; Moriya Y; Hoshino H; Yoshida S; Hanaoka H; Fujii S; Taniguchi M; Yoshino I; Nakayama T
J Clin Immunol; 2012 Oct; 32(5):1071-81. PubMed ID: 22534863
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
Motohashi S; Okamoto Y; Yoshino I; Nakayama T
Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer.
Toyoda T; Kamata T; Tanaka K; Ihara F; Takami M; Suzuki H; Nakajima T; Ikeuchi T; Kawasaki Y; Hanaoka H; Nakayama T; Yoshino I; Motohashi S
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188702
[TBL] [Abstract][Full Text] [Related]
5. [Invariant NKT cell-based immunotherapy for lung cancer and head and neck cancer].
Ihara F; Motohashi S
Nihon Rinsho; 2017 Feb; 75(2):312-316. PubMed ID: 30562870
[TBL] [Abstract][Full Text] [Related]
6. Roles of NKT cells in cancer immunotherapy.
Bae EA; Seo H; Kim IK; Jeon I; Kang CY
Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
[TBL] [Abstract][Full Text] [Related]
7. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
[TBL] [Abstract][Full Text] [Related]
8. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
Front Immunol; 2019; 10():352. PubMed ID: 30881361
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer.
Ishibashi F; Sakairi Y; Iwata T; Moriya Y; Mizobuchi T; Hoshino H; Yoshida S; Hanaoka H; Yoshino I; Motohashi S
Clin Immunol; 2020 Jun; 215():108457. PubMed ID: 32387537
[TBL] [Abstract][Full Text] [Related]
10. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
11. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
12. Novel in vitro invariant natural killer T cell functional assays.
Balasko A; Graydon C; Fowke KR
J Immunol Methods; 2021 Dec; 499():113171. PubMed ID: 34706265
[TBL] [Abstract][Full Text] [Related]
13. Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy.
Watarai H; Yamada D; Fujii S; Taniguchi M; Koseki H
Int J Hematol; 2012 Jun; 95(6):624-31. PubMed ID: 22592322
[TBL] [Abstract][Full Text] [Related]
14. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
Front Immunol; 2018; 9():1266. PubMed ID: 29928278
[TBL] [Abstract][Full Text] [Related]
15. α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials.
Zhang Y; Springfield R; Chen S; Li X; Feng X; Moshirian R; Yang R; Yuan W
Front Immunol; 2019; 10():1126. PubMed ID: 31244823
[TBL] [Abstract][Full Text] [Related]
16. Using agonists for iNKT cells in cancer therapy.
Painter GF; Burn OK; Hermans IF
Mol Immunol; 2021 Feb; 130():1-6. PubMed ID: 33340930
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors.
Li YR; Zhou Y; Wilson M; Kramer A; Hon R; Zhu Y; Fang Y; Yang L
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886891
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
[TBL] [Abstract][Full Text] [Related]
19. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
[TBL] [Abstract][Full Text] [Related]
20. Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner.
Takami M; Aoki T; Nishimura K; Tanaka H; Onodera A; Motohashi S
Cancer Res Commun; 2024 Feb; 4(2):446-459. PubMed ID: 38319156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
